Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study DOI Creative Commons
John Kimotho, Yiakon Sein, Shahin Sayed

et al.

Wellcome Open Research, Journal Year: 2024, Volume and Issue: 8, P. 350 - 350

Published: Dec. 2, 2024

Background Given the low levels of coronavirus disease 2019 (COVID-19) vaccine coverage in sub-Saharan Africa (sSA), despite high natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) exposures, strategies for extending breadth and longevity naturally acquired immunity are warranted. Designing such will require a good understanding immunity. Methods We measured whole-spike immunoglobulin G (IgG) spike-receptor binding domain (RBD) total immunoglobulins (Igs) on 585 plasma samples collected longitudinally over five successive time points within six months COVID-19 diagnosis 309 patients. antibody-neutralising potency against wild-type (Wuhan) SARS-CoV-2 pseudovirus subset 51 patients three points. Binding neutralising antibody potencies were then tested correlations with severities. Results Rates seroconversion increased from day 0 (day PCR testing) to 180 (six months) (63.6% 100 %) (69.3 % 97%) anti-spike-IgG anti-spike-RBD Igs, respectively. Levels these antibodies peaked at 28 (p<0.01) subsequently maintained without significant decay (p>0.99). Similarly, but declined by three-fold, after (p<0.01). highly correlated all analysed (r>0.60, p<0.01). severity. Conclusions Most generated specific that remained stable first infection. However, respective decayed three-fold month-six suggesting they short-lived, consistent what has been observed elsewhere world. Thus, regular vaccination boosters required sustain anti-SARS-CoV-2 our population.

Language: Английский

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study DOI Creative Commons
John Kimotho, Yiakon Sein, Shahin Sayed

et al.

Wellcome Open Research, Journal Year: 2024, Volume and Issue: 8, P. 350 - 350

Published: Dec. 2, 2024

Background Given the low levels of coronavirus disease 2019 (COVID-19) vaccine coverage in sub-Saharan Africa (sSA), despite high natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) exposures, strategies for extending breadth and longevity naturally acquired immunity are warranted. Designing such will require a good understanding immunity. Methods We measured whole-spike immunoglobulin G (IgG) spike-receptor binding domain (RBD) total immunoglobulins (Igs) on 585 plasma samples collected longitudinally over five successive time points within six months COVID-19 diagnosis 309 patients. antibody-neutralising potency against wild-type (Wuhan) SARS-CoV-2 pseudovirus subset 51 patients three points. Binding neutralising antibody potencies were then tested correlations with severities. Results Rates seroconversion increased from day 0 (day PCR testing) to 180 (six months) (63.6% 100 %) (69.3 % 97%) anti-spike-IgG anti-spike-RBD Igs, respectively. Levels these antibodies peaked at 28 (p<0.01) subsequently maintained without significant decay (p>0.99). Similarly, but declined by three-fold, after (p<0.01). highly correlated all analysed (r>0.60, p<0.01). severity. Conclusions Most generated specific that remained stable first infection. However, respective decayed three-fold month-six suggesting they short-lived, consistent what has been observed elsewhere world. Thus, regular vaccination boosters required sustain anti-SARS-CoV-2 our population.

Language: Английский

Citations

0